However, patients with bone metastases had a significantly higher RANKL expression and RANKL: OPG ratio compared to those without bone metastases; possibly because the bone microenvironment in those with bone metastases released cytokines or growth factors which induced RANKL expression also in the tumor. This evidence concerns the gene TNFRSF11B and neoplasm.